18th Sep 2020 20:17
Renalytix AI PLC - Cardiff, Wales-based clinical diagnostics company - Reports commercial launch of KidneyIntelX clinical test reporting platform in New York City's Mount Sinai Health System hospital network. Platform helps risk assess a patient's progressive decline in kidney function.
Current stock price: 522.30 pence
Year-to-date change: up 43%
By Eric Cunha; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Renalytix Plc